Accuray Incorporated (ARAY) stock analysis

Healthcare · Medical Devices

From the 10-K filed 2026-08-27

How it makes money

Accuray generates revenue by selling robotic and helical radiation therapy systems, software, and support services to clinical teams for precise cancer treatments.

Accuray earns its revenue from healthcare providers, hospitals, and cancer centers that purchase radiation treatment equipment and software services. The company's platforms, such as CyberKnife and helical systems like Radixact, enable precise radiosurgery and adaptive radiation therapy.

Profitability depends on market acceptance, gross margins on product sales and services, and maintaining utilization across clinical departments.

What protects it: the moat

Management claims its specialized robotic platforms, multi-specialty clinical utility, and imaging software protect its position, though intellectual property defense remains difficult.

The company asserts that its differentiated CyberKnife robotic platform and helical portfolio provide advanced motion management and imaging workflows that competitors cannot easily replicate. It also relies on patent protections and multi-departmental clinical utilization by both neurosurgeons and radiation oncologists.

However, management notes that protecting proprietary technologies is difficult and costly, and competitors continuously develop alternative radiation therapy technologies.

What growth costs

Accuray must continually invest in clinical studies, software upgrades, product enhancements, physician education, and international market access to support growth.

To maintain market adoption and expand utilization, Accuray sponsors educational symposia, supports clinical studies, and provides marketing tools to healthcare customers. Expanding its product portfolio requires ongoing research and development to update motion management capabilities and treatment planning software.

The text does not disclose specific capital expenditure or research and development figures.

What could damage it

Reliance on single-source suppliers for critical components creates severe supply chain vulnerability that could halt manufacturing operations and impair earnings.

If a single-source supplier fails to deliver critical components, Accuray may be unable to manufacture its radiation therapy systems in a timely or cost-effective manner. This bottleneck could force the company to temporarily cease manufacturing operations, leading to delivery delays, lost revenue, and permanent loss of customers to competing platform providers.

About Accuray Incorporated

Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, a tailored helical solution, which integrates radiation treatment planning, delivery, imaging, and data management; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Other companies in Medical Devices